**Table. S1** Clinical information of individuals enrolled for urinary protein microarray

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Number | Age | Gender | Urinary protein (g/24h) | Creatinine (µmol/L) | eGFR (ml · min−1 · 1.73 m−2) |
| Normal | 1 | 45 | Female | \ | \ | \ |
| Normal | 2 | 53 | Female | \ | \ | \ |
| Normal | 3 | 57 | Male | \ | \ | \ |
| Normal | 4 | 55 | Female | \ | \ | \ |
| Normal | 5 | 58 | Male | \ | \ | \ |
| Normal | 6 | 48 | Male | \ | \ | \ |
| Normal | 7 | 56 | female | \ | \ | \ |
| T2DM | 8 | 43 | Male | \ | 50 | \ |
| T2DM | 9 | 52 | Female | \ | 50 | \ |
| T2DM | 10 | 56 | Female | \ | 52.4 | \ |
| T2DM | 11 | 56 | Female | \ | 96.8 | \ |
| T2DM | 12 | 61 | Female | \ | 52 | \ |
| T2DM | 13 | 63 | Male | \ | 62.9 | \ |
| T2DM | 14 | 61 | Male | \ | 70.3 | \ |
| T2DM | 15 | 66 | Male | \ | 83.5 | \ |
| T2DM | 16 | 71 | Male | \ | 82.1 | \ |
| DN-I | 17 | 57 | Male | 0.93 | 78.2 | 88.72 |
| DN-I | 18 | 46 | Male | 0.18 | 85.6 | 83.49 |
| DN-I | 19 | 39 | Male | 1.25 | 67.8 | 112.98 |
| DN-I | 20 | 56 | Female | 0.27 | 86.3 | 58.97 |
| DN-I | 21 | 52 | Male | 0.45 | 47.9 | 159.14 |
| DN-I | 22 | 41 | Female | 1.20 | 43.9 | 137.04 |
| DN-I | 23 | 41 | Female | 2.50 | 76.3 | 72.41 |
| DN-II | 24 | 55 | Male | 3.64 | 150.3 | 42.05 |
| DN-II | 25 | 46 | Male | 2.80 | 111.8 | 61.99 |
| DN-II | 26 | 56 | Female | 1.50 | 128.2 | 37.35 |
| DN-II | 27 | 48 | Male | 5.07 | 116.1 | 43.21 |
| DN-II | 28 | 57 | Female | 3.25 | 119.5 | 40.36 |
| DN-II | 29 | 59 | Male | 1.80 | 239.0 | 24.27 |
| DN-II | 30 | 63 | Female | 2.20 | 126.2 | 37.13 |
| DN-II | 31 | 53 | Male | 3.00 | 210.3 | 28.75 |
| NDRD | 32 | 49 | Female | 1.26 | 58.2 | 95.46 |
| NDRD | 33 | 67 | Female | 2.52 | 72.9 | 88.06 |
| NDRD | 34 | 53 | Male | 0.56 | 97.4 | 69.73 |
| NDRD | 35 | 41 | Male | 2.48 | 61.0 | 126.35 |
| NDRD | 36 | 47 | Male | 0.45 | 75.4 | 96.23 |
| NDRD | 37 | 57 | Female | 3.00 | 73.6 | 70.60 |
| NDRD | 38 | 56 | Male | 4.50 | 50.6 | 147.15 |
| NDRD | 39 | 48 | Male | 1.80 | 93.9 | 74.39 |
| NDRD | 40 | 52 | Male | 2.29 | 150.6 | 42.43 |
| NDRD | 41 | 35 | Male | 1.33 | 88.6 | 84.81 |
| NDRD | 42 | 35 | Male | 1.96 | 133.2 | 52.98 |
| NDRD | 43 | 34 | Male | 1.51 | 148.1 | 47.16 |
| NDRD | 44 | 49 | Male | 0.12 | 83.6 | 84.70 |
| NDRD | 45 | 65 | Male | 4.32 | 79.4 | 84.88 |
| NDRD | 46 | 54 | Male | 0.53 | 83.2 | 83.51 |
| NDRD | 47 | 48 | Male | 1.21 | 178.1 | 35.54 |
| NDRD | 48 | 44 | Female | 0.60 | 63.5 | 88.23 |

**Table. S2** The normalized fluorescent intensities for each lectin in HVs, T2DM, DN groups, MN and IgAN by the lectin microarray analysis based on data of 37 lectins*a*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Lectin | HVs | T2DM | DN group I | DN group II | MN | IgAN |
| Jacalin | / | / | / | / | 0.071 ± 0.002 | / |
| ECA | / | / | / | / | / | / |
| HHL | / | / | / | / | / | / |
| WFA | / | / | / | / | / | / |
| GSL-II | / | / | / | / | / | / |
| MAL-II | / | / | 0.042 ± 0.004 | / | / | / |
| PHA-E | / | / | / | / | / | / |
| PTL-I | / | / | 0.050 ± 0.008 | / | / | / |
| SJA | / | / | 0.058 ± /0.006 | / | / | / |
| PNA | / | / | / | / | / | / |
| EEL | / | / | / | / | / | / |
| AAL | 0.022 ± 0.008 | / | 0.073 ± 0.017 | / | / | 0.113 ± 0.043 |
| LTL | / | / | / | / | / | / |
| MPL | / | / | / | / | / | / |
| LEL | 0.026 ± 0.003 | / | / | / | / | / |
| GSL-I | / | / | / | / | / | / |
| DBA | / | / | 0.053 ± 0.007 | / | / | / |
| LCA | / | / | / | / | / | / |
| RCA120 | 0.200 ± 0.043 | 0.160 ± 0.015 | 0.209 ± 0.026 | 0.234 ± 0.009 | 0.956 ± 0.040 | 0.120 ± 0.025 |
| STL | 1 ± 0 | 1 ± 0 | / | / | 0.129 ± 0.006 | 1 ± 0 |
| BS-I | 0.081 ± 0.018 | 0.051 ± 0.004 | 0.082 ± 0.017 | 0.045 ± 0.006 | 0.199 ± 0.022 | / |
| ConA | / | / | / | 0.027 ± 0.001 | / | / |
| PTL-II | / | / | 0.041 ± 0.004 | / | / | / |
| DSA | 0.348 ± 0.057 | 0.074 ± 0.008 | 1 ± 0 | 1 ± 0 | 0.996 ± 0.006 | 0.305 ± 0.040 |
| SBA | 0.162 ± 0.047 | 0.052 ± 0.006 | 0.189 ± 0.058 | / | / | 0.041 ± 0.002 |
| VVA | / | / | / | / | / | / |
| NPA | / | / | / | / | / | / |
| PSA | 0.031 ± 0.007 | 0.041 ± 0.005 | 0.047 ± 0.011 | / | 0.102 ± 0.022 | / |
| ACA | 0.017 ± 0.003 | / | / | / | / | / |
| WGA | 0.043 ± 0.008 | / | / | / | / | / |
| UEA-I | / | / | / | / | 0.066 ± 0.013 | / |
| PWM | 0.081 ± 0.014 | 0.048 ± 0.016 | 0.085 ± 0.020 | 0.044 ± 0.003 | 0.169 ± 0.020 | 0.070 ± 0.008 |
| MAL-I | / | / | / | / | / | / |
| GNA | 0.089 ± 0.016 | 0.131 ± 0.012 | 0.214 ± 0.041 | 0.105 ± 0.009 | 0.143 ± 0.008 | 0.056 ± 0.011 |
| BPL | / | / | / | / | / | / |
| PHA-E+L | / | / | 0.041 ± 0.009 | / | / | / |
| SNA | 0.065 ± 0.010 | 0.089 ± 0.004 | 0.280 ± 0.079 | 0.7131 ± 0.071 | 0.279 ± 0.015 | 0.1561 ± 0.041 |

*a*Normalized fluorescent intensities (NFI) obtained for three repeated slides were averaged and its SD was counted; /, negative signals. HVs, healthy volunteers; T2DM, type 2 diabetic mellitus; DN diabetic nephropathy; MN, membranous nephropathy; IgAN, IgA nephropathy.